Drug intelligence / Profile preview

ONO-2333Ms

Development stage: Phase 2
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ONO-2333Ms is a small molecule drug developed by Ono Pharmaceutical as an orally active antagonist of the corticotropin-releasing factor 1 (CRF1) receptor. It was investigated for the treatment of major depressive disorder and anxiety disorders. The drug acts by blocking CRF1 receptors, which are involved in mediating stress responses and are implicated in the pathophysiology of depression and anxiety. Clinical development reached Phase II for major depressive disorder but was discontinued without further progression[1][2][3][7].

Other names: 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-UNII-T989JBG788UNII-T-989JBG788UNII-T 989JBG788

Targets

CRHR1 (Corticotropin-releasing factor receptor 1)

Beyond the preview

Go deeper on ONO-2333Ms.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONO-2333Ms.

Explore the full profile